Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Human epidermal growth factor receptor 2 (HER2)-low expression in breast cancer has been recently identified as a new therapeutic target. However, it is unclear if HER2-low status has an independent impact on prognosis.

Materials and methods

A systematic literature research was carried out to identify studies comparing survival outcomes of patients affected by HER2-low versus HER2-zero breast cancer. Using random-effects models, pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for progression-free survival (PFS) and overall survival (OS) in the metastatic setting as well as disease-free survival (DFS), OS and pathological complete response (pCR) in the early setting. Subgroup analyses by hormone receptor (HoR) st

SUBMITTER: Molinelli C 

PROVIDER: S-EPMC10485402 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature